📇 Rhumatologue · SAVIGNY SUR ORGE · (91) · Salarié

M Albert-Hervé COHEN

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
37 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
4 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
73.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 SAVIGNY SUR ORGE (91)SalariéRPPS 10000879626

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(4)

COSAYA
18 BOULEVARD ARISTIDE BRIAND, 91600 SAVIGNY SUR ORGE
Activité de soin et de pharmacie
COSAYA
42 RUE FRANCOEUR, 91170 VIRY CHATILLON
Activité de soin et de pharmacie
IRM D EVRY
2-4 2 AV DE MOUSSEAU, 91035 EVRY CEDEX
☎ 0160772986

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Genetic correlates of vitamin D-binding protein and 25-hydroxyvitamin D in neonatal dried blood spots

Nature communications · 2023

📚 27 citations🎯 RCR 3.31Top 14% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract The vitamin D binding protein (DBP), encoded by the group-specific component ( GC ) gene, is a component of the vitamin D system. In a genome-wide association study of DBP concentration in 65,589 neonates we identify 26 independent loci, 17 of which are in or close to the GC gene, with fine-mapping identifying 2 missense variants on chromosomes 12 and 17 (within SH2B3 and GSDMA , respectively). When adjusted for GC haplotypes, we find 15 independent loci distributed over 10 chromosomes. Mendelian randomization analyses identify a unidirectional effect of higher DBP concentration and (a) higher 25-hydroxyvitamin D concentration, and (b) a reduced risk of multiple sclerosis and rheumatoid arthritis. A phenome-wide association study confirms that higher DBP concentration is associated with a reduced risk of vitamin D deficiency. Our findings provide valuable insights into the influence of DBP on vitamin D status and a range of health outcomes.

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry

Kidney360 · 2023

📚 17 citations🎯 RCR 2.14Top 25% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Key Points IgAN and MCD are the most common de novo glomerular diseases reported after COVID-19 vaccination, particularly after mRNA vaccination.Membranous nephropathy, pauci-immune GN, and collapsing GN have also been attributed to COVID-19 vaccination, some with dual histologies.Recovery of kidney function and proteinuria remission is more likely in IgAN and MCD by 4–6 months compared with the other glomerular diseases. Background Patients with de novo glomerular disease (GD) with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established, and the long-term outcomes are not known. To better characterize the GDs and clinical courses/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis to study in aggregate patients with de novo GN suspected after COVID-19 vaccine exposure. Methods A REDCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and GD histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes. Results Ninety-eight patients with GD were entered into the registry over 11 months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most common kidney diseases reported. Recovery of kidney function and remission of proteinuria were more likely in IgAN and MCD at 4–6 months than with pauci-immune GN/vasculitis and membranous nephropathy. Conclusions The development of GD after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment are recommended based on these findings.

Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023

📚 17 citations🎯 RCR 3.11Top 15% NIH🩺 Clinique

Lire l'abstract Crossref ↓

AbstractPremenopausal women with idiopathic osteoporosis (PreMenIOP) have marked deficits in skeletal microstructure. We have reported that sequential treatment with teriparatide and denosumab improves central skeletal bone mineral density (BMD) by dual-energy X-ray absorptiometry and central QCT in PreMenIOP. We conducted preplanned analyses of high-resolution peripheral quantitative computed tomography (HR-pQCT) scans from teriparatide and denosumab extension studies to measure effects on volumetric BMD (vBMD), microarchitecture, and estimated strength at the distal radius and tibia. Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study. HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months. After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months. Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab. Changes after sequential teriparatide and denosumab were secondary outcomes. After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p &lt; 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: −5.1%, all p &lt; 0.02). Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites. After denosumab, increases in total (3.5%, p &lt; 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p &lt; 0.01), and failure load (1.1% and 3.6%; both p &lt; 0.05) were seen at tibia and radius, respectively. Trabecular density (3.5%, p &lt; 0.001) and number (2.4%, p = 0.03) increased at the tibia, while thickness (3.0%, p = 0.02) increased at the radius. After 48 months of sequential treatment, significant increases in total vBMD (tibia: p &lt; 0.001; radius: p = 0.01), trabecular microstructure (p &lt; 0.05), cortical thickness (tibia: p &lt; 0.001; radius: p = 0.02), and whole bone strength (p &lt; 0.02) were seen at both sites. Significant increases in total vBMD and bone strength parameters after sequential treatment with teriparatide followed by denosumab support the use of this regimen in PreMenIOP. © 2022 American Society for Bone and Mineral Research (ASBMR).

Cookies & analyse de trafic

M Albert-Hervé COHEN

Pourquoi vous devez consulter ce praticien

Lieux de consultation(4)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (37) — classées par pathologie

Transversal10

Épidémiologie & registres6

Génétique3

Ostéoporose3

Revue générale3

Goutte2

Vraie vie / RWE2

Anti-IL-171

Case report / série1

Corticothérapie1

Essai clinique1

Lupus1

Maladie de Horton1

Revue / méta-analyse1

Risque cardio-vasculaire1

SAPL1

Vascularites1

Partager cette fiche